Enterobacteriaceae Infection Drug Market, Global Outlook and Forecast 2022-2028

March 2022 | 60 pages | ID: EF19DE4E0C44EN
Market Monitor Global

Abstracts

Enterobacteriaceae infections are caused by Enterobacter species, pathogens responsible for causing severe infections including bacteremia, urinary tract infections, lower respiratory tract infections, skin and soft tissue infections, and intra-abdominal infections.

This report contains market size and forecasts of Enterobacteriaceae Infection Drug in Global, including the following market information:

Global Enterobacteriaceae Infection Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Enterobacteriaceae Infection Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Beta-lactams Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Enterobacteriaceae Infection Drug include Genentech, Nanotherapeutics, Novartis, Pfizer, Nymox Pharmaceutical, Sequoia Sciences, Phico Therapeutics and Cantab Biopharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Enterobacteriaceae Infection Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Enterobacteriaceae Infection Drug Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Enterobacteriaceae Infection Drug Market Segment Percentages, by Type, 2021 (%)

• Beta-lactams Drugs
• Carbapenems Drugs
• Fluoroquinolones Drugs
• Others

Global Enterobacteriaceae Infection Drug Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Enterobacteriaceae Infection Drug Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Enterobacteriaceae Infection Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Enterobacteriaceae Infection Drug Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Enterobacteriaceae Infection Drug revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Enterobacteriaceae Infection Drug revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Genentech
• Nanotherapeutics
• Novartis
• Pfizer
• Nymox Pharmaceutical
• Sequoia Sciences
• Phico Therapeutics
• Cantab Biopharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Enterobacteriaceae Infection Drug Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Enterobacteriaceae Infection Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL ENTEROBACTERIACEAE INFECTION DRUG OVERALL MARKET SIZE

2.1 Global Enterobacteriaceae Infection Drug Market Size: 2021 VS 2028
2.2 Global Enterobacteriaceae Infection Drug Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Enterobacteriaceae Infection Drug Players in Global Market
3.2 Top Global Enterobacteriaceae Infection Drug Companies Ranked by Revenue
3.3 Global Enterobacteriaceae Infection Drug Revenue by Companies
3.4 Top 3 and Top 5 Enterobacteriaceae Infection Drug Companies in Global Market, by Revenue in 2021
3.5 Global Companies Enterobacteriaceae Infection Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Enterobacteriaceae Infection Drug Players in Global Market
  3.6.1 List of Global Tier 1 Enterobacteriaceae Infection Drug Companies
  3.6.2 List of Global Tier 2 and Tier 3 Enterobacteriaceae Infection Drug Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Enterobacteriaceae Infection Drug Market Size Markets, 2021 & 2028
  4.1.2 Beta-lactams Drugs
  4.1.3 Carbapenems Drugs
  4.1.4 Fluoroquinolones Drugs
  4.1.5 Others
4.2 By Type - Global Enterobacteriaceae Infection Drug Revenue & Forecasts
  4.2.1 By Type - Global Enterobacteriaceae Infection Drug Revenue, 2017-2022
  4.2.2 By Type - Global Enterobacteriaceae Infection Drug Revenue, 2023-2028
  4.2.3 By Type - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Enterobacteriaceae Infection Drug Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacies
  5.1.3 Retail Pharmacies
  5.1.4 Online Pharmacies
5.2 By Application - Global Enterobacteriaceae Infection Drug Revenue & Forecasts
  5.2.1 By Application - Global Enterobacteriaceae Infection Drug Revenue, 2017-2022
  5.2.2 By Application - Global Enterobacteriaceae Infection Drug Revenue, 2023-2028
  5.2.3 By Application - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Enterobacteriaceae Infection Drug Market Size, 2021 & 2028
6.2 By Region - Global Enterobacteriaceae Infection Drug Revenue & Forecasts
  6.2.1 By Region - Global Enterobacteriaceae Infection Drug Revenue, 2017-2022
  6.2.2 By Region - Global Enterobacteriaceae Infection Drug Revenue, 2023-2028
  6.2.3 By Region - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Enterobacteriaceae Infection Drug Revenue, 2017-2028
  6.3.2 US Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.3.3 Canada Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.3.4 Mexico Enterobacteriaceae Infection Drug Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Enterobacteriaceae Infection Drug Revenue, 2017-2028
  6.4.2 Germany Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.4.3 France Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.4.4 U.K. Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.4.5 Italy Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.4.6 Russia Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.4.7 Nordic Countries Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.4.8 Benelux Enterobacteriaceae Infection Drug Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Enterobacteriaceae Infection Drug Revenue, 2017-2028
  6.5.2 China Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.5.3 Japan Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.5.4 South Korea Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.5.5 Southeast Asia Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.5.6 India Enterobacteriaceae Infection Drug Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Enterobacteriaceae Infection Drug Revenue, 2017-2028
  6.6.2 Brazil Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.6.3 Argentina Enterobacteriaceae Infection Drug Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Enterobacteriaceae Infection Drug Revenue, 2017-2028
  6.7.2 Turkey Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.7.3 Israel Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.7.4 Saudi Arabia Enterobacteriaceae Infection Drug Market Size, 2017-2028
  6.7.5 UAE Enterobacteriaceae Infection Drug Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Genentech
  7.1.1 Genentech Corporate Summary
  7.1.2 Genentech Business Overview
  7.1.3 Genentech Enterobacteriaceae Infection Drug Major Product Offerings
  7.1.4 Genentech Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
  7.1.5 Genentech Key News
7.2 Nanotherapeutics
  7.2.1 Nanotherapeutics Corporate Summary
  7.2.2 Nanotherapeutics Business Overview
  7.2.3 Nanotherapeutics Enterobacteriaceae Infection Drug Major Product Offerings
  7.2.4 Nanotherapeutics Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
  7.2.5 Nanotherapeutics Key News
7.3 Novartis
  7.3.1 Novartis Corporate Summary
  7.3.2 Novartis Business Overview
  7.3.3 Novartis Enterobacteriaceae Infection Drug Major Product Offerings
  7.3.4 Novartis Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
  7.3.5 Novartis Key News
7.4 Pfizer
  7.4.1 Pfizer Corporate Summary
  7.4.2 Pfizer Business Overview
  7.4.3 Pfizer Enterobacteriaceae Infection Drug Major Product Offerings
  7.4.4 Pfizer Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
  7.4.5 Pfizer Key News
7.5 Nymox Pharmaceutical
  7.5.1 Nymox Pharmaceutical Corporate Summary
  7.5.2 Nymox Pharmaceutical Business Overview
  7.5.3 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Major Product Offerings
  7.5.4 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
  7.5.5 Nymox Pharmaceutical Key News
7.6 Sequoia Sciences
  7.6.1 Sequoia Sciences Corporate Summary
  7.6.2 Sequoia Sciences Business Overview
  7.6.3 Sequoia Sciences Enterobacteriaceae Infection Drug Major Product Offerings
  7.6.4 Sequoia Sciences Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
  7.6.5 Sequoia Sciences Key News
7.7 Phico Therapeutics
  7.7.1 Phico Therapeutics Corporate Summary
  7.7.2 Phico Therapeutics Business Overview
  7.7.3 Phico Therapeutics Enterobacteriaceae Infection Drug Major Product Offerings
  7.7.4 Phico Therapeutics Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
  7.7.5 Phico Therapeutics Key News
7.8 Cantab Biopharmaceuticals
  7.8.1 Cantab Biopharmaceuticals Corporate Summary
  7.8.2 Cantab Biopharmaceuticals Business Overview
  7.8.3 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Major Product Offerings
  7.8.4 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Revenue in Global Market (2017-2022)
  7.8.5 Cantab Biopharmaceuticals Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Enterobacteriaceae Infection Drug Market Opportunities & Trends in Global Market
Table 2. Enterobacteriaceae Infection Drug Market Drivers in Global Market
Table 3. Enterobacteriaceae Infection Drug Market Restraints in Global Market
Table 4. Key Players of Enterobacteriaceae Infection Drug in Global Market
Table 5. Top Enterobacteriaceae Infection Drug Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Enterobacteriaceae Infection Drug Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Enterobacteriaceae Infection Drug Revenue Share by Companies, 2017-2022
Table 8. Global Companies Enterobacteriaceae Infection Drug Product Type
Table 9. List of Global Tier 1 Enterobacteriaceae Infection Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Enterobacteriaceae Infection Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Enterobacteriaceae Infection Drug Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Enterobacteriaceae Infection Drug Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Enterobacteriaceae Infection Drug Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Enterobacteriaceae Infection Drug Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Enterobacteriaceae Infection Drug Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Enterobacteriaceae Infection Drug Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2023-2028
Table 30. Genentech Corporate Summary
Table 31. Genentech Enterobacteriaceae Infection Drug Product Offerings
Table 32. Genentech Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
Table 33. Nanotherapeutics Corporate Summary
Table 34. Nanotherapeutics Enterobacteriaceae Infection Drug Product Offerings
Table 35. Nanotherapeutics Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Enterobacteriaceae Infection Drug Product Offerings
Table 38. Novartis Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer Enterobacteriaceae Infection Drug Product Offerings
Table 41. Pfizer Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
Table 42. Nymox Pharmaceutical Corporate Summary
Table 43. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Product Offerings
Table 44. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
Table 45. Sequoia Sciences Corporate Summary
Table 46. Sequoia Sciences Enterobacteriaceae Infection Drug Product Offerings
Table 47. Sequoia Sciences Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
Table 48. Phico Therapeutics Corporate Summary
Table 49. Phico Therapeutics Enterobacteriaceae Infection Drug Product Offerings
Table 50. Phico Therapeutics Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)
Table 51. Cantab Biopharmaceuticals Corporate Summary
Table 52. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Product Offerings
Table 53. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Enterobacteriaceae Infection Drug Segment by Type in 2021
Figure 2. Enterobacteriaceae Infection Drug Segment by Application in 2021
Figure 3. Global Enterobacteriaceae Infection Drug Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Enterobacteriaceae Infection Drug Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Enterobacteriaceae Infection Drug Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Enterobacteriaceae Infection Drug Revenue in 2021
Figure 8. By Type - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
Figure 9. By Application - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
Figure 10. By Region - Global Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
Figure 11. By Country - North America Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
Figure 12. US Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
Figure 16. Germany Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 17. France Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
Figure 24. China Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 28. India Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
Figure 30. Brazil Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Enterobacteriaceae Infection Drug Revenue Market Share, 2017-2028
Figure 33. Turkey Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Enterobacteriaceae Infection Drug Revenue, (US$, Mn), 2017-2028
Figure 37. Genentech Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Nanotherapeutics Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Sequoia Sciences Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Phico Therapeutics Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)